安进

Long after the national spotlight faded from Southern California’s devastating wildfires in early 2025, these communities and the people within them remain in a state of recovery. As fires burned in January, organizations like Direct Relief rushed in to help, and continue to help today. Amgen and the Amgen Foundation supported this effort through a donation of $10 million which went to wildfires relief efforts led by the California Community Foundation, the United Way of Greater Los Angeles, and Direct Relief. Headquartered in Thousand Oaks, California, Amgen and its employees have called Southern California its home for more than four decades and its connection to the community runs deep. As the road to recovery continues, we remain committed to helping these communities rebuild. ?? Read more here: https://lnkd.in/g66_NmWq

Use of new technologies and real-world data (RWD) can play a critical role in improving data quality. Guided by the capabilities of our Center for Observational Research team, Amgen partnered with other industry leaders on a demonstration project exploring how leveraging #RWD can improve data reliability to inform regulatory decision-making. For patients, this could mean more accurate diagnoses, treatment plans, and better outcomes. Dive deeper into these findings: https://amgen.ly/3DRXk4s

Many people may not be aware of the connection between chronic kidney disease (#CKD) and #gout. The kidneys have many functions, including removing excess uric acid from the body. Without proper removal, high uric acid levels can increase the risk of gout. ? This #NationalKidneyMonth, we’re committed to raising awareness of the CKD and gout connection as we work to improve gout diagnosis and treatment, support patients who live with these serious conditions and share resources for the community. ? ?? Take our poll below and we’ll drop the answer in the comments at the end of the week ??

What if we could help redefine the future of atopic dermatitis? ?? ? At the American Academy of Dermatology’s 2025 conference, Amgen and Kyowa Kirin, Inc.- U.S. spotlighted our shared commitment to advancing the science of atopic dermatitis. Through this partnership, we are deepening our understanding of T-cell imbalance and the OX40 receptor, unlocking new insights for those living with moderate-to-severe #atopicdermatitis. ? Watch for an inside look into this year’s #AAD2025.

Over 48 million women in the U.S. are affected by heart disease. Yet, too often, symptoms are overlooked, risks go unrecognized, and women are misdiagnosed. At Amgen, we’re working to change that, and our focus is on action: raising awareness, educating, and ensuring more women understand their heart health. Hear more from Celina Gorre, CEO of WomenHeart: The National Coalition for Women with Heart Disease, on why understanding your LDL (“bad”) cholesterol and Lp(a) matters: https://amgen.ly/4bPePyR

At Amgen, we are advancing the science behind respiratory diseases, like severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), by exploring the role of epithelial dysfunction as a key driver of disease progression.? ? By deepening our understanding of these mechanisms, we aim to transform what’s possible for people living with respiratory conditions. ?? Learn more: https://amgen.ly/EpicMedL

DERMATOLOGY NEWS: Amgen and Kyowa Kirin, Inc.- U.S. provide an update on the Phase 3 IGNITE study in moderate to severe #atopicdermatitis. ?? Press release: https://amgen.ly/41ABdau

We?continue to gain valuable insights from patient advocates living with obesity, like Michele — helping us understand the realities of living with this complex, chronic disease. This #WorldObesityDay, we recognize the one billion people worldwide living with obesity and related conditions and understand the urgent need for stigma-free, comprehensive care. ?? Learn more about our approach at amgen.com/obesity.?

An Amgen career is full of opportunity. Through our competitive benefits, you can accomplish your best work and live your best life, all while impacting patients worldwide. Learn more about the support we offer and how you can thrive with us: https://lnkd.in/dUXJcQiF

Amgen is at the American Academy of Allergy, Asthma and Immunology - AAAAI and World Allergy Organization Joint Congress, presenting results from the WAYPOINT study in chronic rhinosinusitis with nasal polyps (CRSwNP). The data, which were simultaneously published in NEJM Group, highlight the potential of targeting inflammation at the epithelium. ?? Learn more: https://amgen.ly/3Dh49wf #AAAAI25